IL6 and metabolic syndrome: (29) found that four-week oral sodium butyrate supplementation in participants with metabolic syndrome showed that oral sodium butyrate did not influence the cytokine-producing capacity of PBMC assessed by measuring IL-1β, IL-1Ra, IL-6, and IL-10 upon bacterial stimulation.